User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 23 results.
    • Speech
    Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.
    Rubio, ED Humblet, Yves[UCL] Tabernero, J. Van Cutsem, E. Cervantes, A. André, Thibaut[UCL] Soulie, P Corretge, S Kisker, O. de Gramont, A. (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Journal article
    Belgian Guidelines for HER2testing in gastric cancer
    Jouret-Mourin, Anne[UCL] Hoorens, A. Kockx, M. De Metter, P. Van Cutsem, E. (2011) Belgian Journal of Medical Oncology — Vol. 5 , p. 14-22 (2011)
    • Speech
    Screening for a geriatric risk profile in older cancer patients: a comparative study of the predictive validity of three screening tools
    Kenis, C.[UCL] Schuermans, H.[UCL] Van Cutsem, E.[UCL] Verhoef, G.[UCL] Vansteenkiste, J.[UCL] Vergote, Ignace[UCL] Schoffski, Patrick[UCL] Milisen, K.[UCL] Flamaing, J.[UCL] Wildiers, H.[UCL] (2009) 10th Meeting of the International-Society-of-the-Geriatric-Oncology — Berlin(Germany)
    • Speech
    A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data
    Vergote, IB Humblet, Yves Van Cutsem, E. Van Belle, S. Kerger, Joseph Van Laethem, JL Canon, JL. Forget, F. Strobbe, E Van Oosterom, A. (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Journal article
    Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D. Humblet, Yves[UCL] Siena, S. Khayat, D Bleiberg, H. Santoro, A. Bets, D. Mueser, M Harstrick, A Verslype, C. Chau, I Van Cutsem, E. (2004) New England Journal of Medicine — Vol. 351, no. 4, p. 337-45 (2004)
    • Speech
    Intrinsic Resistance To the Antiproliferative Effects of Azd6244 a Selective Mek1/2 Inhibitor Is Associated With Concomitant K-ras and Pi3kca Gene Mutations in Colorectal Cancer Cells
    Troiani, T. Vecchione, I. Capasso, A. Martinelli, E. Caraglia, M. Marra, M. De Roock, Wendy[UCL] Tejpar, Sabine[UCL] Van Cutsem, E.[UCL] Ciardiello, F. (2010) 12th World Congress on Gastrointestinal Cancer — Barcelona(Spain)
    • Journal article
    EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients
    Pallis, A. G.[UCL] Papamichael, D. Audisio, R. Peeters, Marie-Rose[UCL] Folprecht, G. Lacombe, Denis[UCL] Van Cutsem, E.[UCL] (2010) Cancer Treatment Reviews — Vol. 36, no. 1, p. 83-90 (2010)
    • Speech
    Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study
    Hompes, D.[UCL] D'Hoore, A.[UCL] Van Cutsem, E.[UCL] Ceelen, W.[UCL] Peeters, Marie-Rose[UCL] Van der Speeten, K.[UCL] Bertrand, C.[UCL] Kerger, Joseph Legendre, H.[UCL] (2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando(Fl)
    • Speech
    An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.
    Tabernero, JM Humblet, Yves[UCL] Van Cutsem, E. Sastre, J. Cervantes, A. Van Laethem, JL Soulie, P Corretge, S Mueser, M de Gramont, A. (2004) 40th Annual Meeting of the American-Society-of-Clinical-Oncology — New Orleans (La)
    • Speech
    A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents.
    Teipar, S Humblet, Yves[UCL] Lin, E Bono, P Jalava, T Kay, A Masson, E Laurent, D Joensuu, H Van Cutsem, E. (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Journal article
    A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
    Van Cutsem, E. Humblet, Yves[UCL] Pozzo, C Starkhammar, H Dirix, L. Terzoli, E Cognetti, E Garufi, C Filez, L Gruia, G Cote, C Barone, C (1998) Annals of Oncology — Vol. 9, no. 11, p. 1199-1204 (1998)
    • Journal article
    Compassionate use of Gemzar in advanced pancreatic cancer: a Belgian experience.
    Humblet, Yves[UCL] Van Cutsem, E.[UCL] Dubois, Christine[UCL] Gillard, P (2001) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 64, no. 4, p. 305-308 (2001)
    • Journal article
    Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    Van Cutsem, E. Cunningham, D. Huinink, WWT. Punt, CJA Alexopoulos, C.G. Dirix, L. Symann, Michel[UCL] Blijham, GH Cholet, P Fillet, G. Van Groeningen, C Vannetzel, JM Levi, F Panagos, G Unger, C. Wils, J. Cote, C Blanc, C Herait, P Bleiberg, H. (1999) European Journal of Cancer — Vol. 35, no. 1, p. 54-59 (1999)
    • Journal article
    Psychological implications of living with familial adenomatous polyposis
    Claes, E. Renson, M. Delespesse, A. De Hoe, V. Haelterman, G. Kartheuser, Alex[UCL] Van Cutsem, E. (2011) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 74, no. 3, p. 438-444 (2011)
    • Journal article
    FAPA - familial adenomatous polyposis association: the Belgian Polyposis Registry
    Kartheuser, Alex[UCL] Laurent, S. Franchimont, D. Van Cutsem, E. (2011) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 74, no. 3, p. 413-414 (2011)
    • Journal article
    Different surgical strategies in the treatment of familial adenomatous polyposis : what's the role of the ileal pouch-anal anastomosis?
    Leonard, Daniel[UCL] Wolthuis, A. D'Hoore, A. Bruyninx, L. Van De Stadt, J. Van Cutsem, E. Kartheuser, Alex[UCL] (2011) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 74, no. 3, p. 427-434 (2011)
    • Journal article
    Quality of care indicators in rectal cancer
    Demetter, P. Ceelen, W. Danse, Etienne[UCL] Haustermans, K. Mourin, Anne[UCL] Kartheuser, Alex[UCL] Laurent, S. Mollet, G. Nagy, N. Scalliet, Pierre[UCL] Van Cutsem, E. Van Den Eynde, Marc[UCL] Van de Stadt, J. Van Eycken, E. Van Laethem, J. L. Vindevoghel, K. Penninckx, F. (2011) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 74, no. 3, p. 445-450 (2011)
    • Speech
    Report on the Belgian consensus meeting on Colorectal cancer screening
    Adler, M. De Vos, M Dufour, A Janssens, J. Laurent, S.[UCL] Melange, Michel Polus, M. Op de Beeck, B Schapira, M. Van Cutsem, E. Van Gossum, A (2005) Joint Meeting of the European-Society-of-Gastrointestinal-Endoscopy (ESGE) — Oslo(Norway)
    • Journal article
    Familial adenomatous polyposis: clinical presentation, detection and surveillance
    Laurent, S. Franchimont, D. Coppens, J. P. Leunen, K. Macken, L. Peeters, M. Plomteux, O. Polus, M. Poppe, B. Sempoux, Christine[UCL] Tejpar, S. Van Den Eynde, Marc[UCL] Van Gossum, A. Vannoote, J. Kartheuser, Alex[UCL] Van Cutsem, E.[UCL] (2011) Acta Gastro-Enterologica Belgica (Multilingual Edition) — Vol. 74, no. 3, p. 415-420 (2011)
    • Speech
    PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
    Siena, S. Elez, E. Peeters, M. André, T. Van den Eynde, Marc[UCL] Ng, K. Cercek, A. Fountzilas, C. Sanchez, F. Hubbard, J. Wu, C. Tabernero, J. Kardosh, A. Saeed, A. Strickler, J. Bekaii-Saab, T. Stecher, M. Palanca-Wessels, M. Van Cutsem, E. (2021) ESMO World Congress on Gastrointestinal Cancer 2021 —
    • Speech
    O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
    Ajani, J. El Hajbi, F. Cunningham, D. Alsina, M. Thuss-Patience, P. Scagliotti, G. Van den Eynde, Marc[UCL] Rybkin, I. Shen, L. Kato, K. Kim, S. D’Alonzo, S. Yu, W. Tao, A. Van Cutsem, E. (2021) ESMO World Congress on Gastrointestinal Cancer 2021 —
    • Speech
    Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer
    Van Cutsem, E. Machiels, J. Van den Eynde, Marc[UCL] Prenen, H. Hendlisz, A. Shaza, L. Carrasco, J. Canon, J. Sotiropoulou, P. Breman, E. Alcantar, E. Flament, A. (2019) ESMO Congress 2019 —
    • Speech
    Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers
    Van Cutsem, E. Melichar, B. Van den Eynde, Marc[UCL] Prausova, J. Geboes, K. Dekervel, J. Vitaskova, D. De Cuyper, A. Linke, Z. Van Acker, N. Frenois, F. Noel, G. Prost, J. Barret, J. Jean, B. Tabah-Fisch, I. (2019) ESMO Congress 2019 —